IRAK kinase inhibitors
The invention discloses an IRAK kinase inhibitor, and discloses a compound with a structure as shown in a formula I, a deuterated substance, a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and application of the compound, the deuterated substance, the stereoisomer or the pharmaceutically acceptable salt. The compound provided by the invention has a good IRAK1/4 kinase inhibition effect, and is a novel and high-activity IRAK1/4 inhibitor. # imgabs0 #.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 12. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LU JIAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-12, Last update posted on www.tib.eu: 2024-05-06, Last updated: 2024-05-10 |
|---|
| Patentnummer: |
CN117209489 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000484040 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000484040 | ||
| 003 | DE-627 | ||
| 005 | 20240510111105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000484040 | ||
| 035 | |a (EPA)CN117209489 | ||
| 035 | |a (EPA)89043227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LU JIAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IRAK kinase inhibitors |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-12, Last update posted on www.tib.eu: 2024-05-06, Last updated: 2024-05-10 | ||
| 520 | |a The invention discloses an IRAK kinase inhibitor, and discloses a compound with a structure as shown in a formula I, a deuterated substance, a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and application of the compound, the deuterated substance, the stereoisomer or the pharmaceutically acceptable salt. The compound provided by the invention has a good IRAK1/4 kinase inhibition effect, and is a novel and high-activity IRAK1/4 inhibitor. # imgabs0 # | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a QING YALI |e verfasserin |4 aut | |
| 700 | 0 | |a HUANG XUEHUI |e verfasserin |4 aut | |
| 700 | 0 | |a REN YUEYING |e verfasserin |4 aut | |
| 700 | 0 | |a SONG NA |e verfasserin |4 aut | |
| 700 | 0 | |a YANG XIN |e verfasserin |4 aut | |
| 700 | 0 | |a WEN QIAODONG |e verfasserin |4 aut | |
| 700 | 0 | |a ZHUGE DINGJUAN |e verfasserin |4 aut | |
| 700 | 0 | |a ZHENG MEI |e verfasserin |4 aut | |
| 700 | 0 | |a YIN JIANMING |e verfasserin |4 aut | |
| 700 | 0 | |a LYU YUBIN |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 12. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:12 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89043227/publication/CN117209489A1?q=CN117209489 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 12 |c 12 | ||